Cargando…

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse effect of ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26.COV2.S COVID-19 vaccine, and it is associated with unusual thrombosis. VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greinacher, Andreas, Selleng, Kathleen, Mayerle, Julia, Palankar, Raghavendra, Wesche, Jan, Reiche, Sven, Aebischer, Andrea, Warkentin, Theodore E., Muenchhoff, Maximilian, Hellmuth, Johannes C., Keppler, Oliver T., Duerschmied, Daniel, Lother, Achim, Rieg, Siegbert, Gawaz, Meinrad Paul, Mueller, Karin Anne Lydia, Scheer, Christian S., Napp, Matthias, Hahnenkamp, Klaus, Lucchese, Guglielmo, Vogelgesang, Antje, Flöel, Agnes, Lovreglio, Piero, Stufano, Angela, Marschalek, Rolf, Thiele, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Thrombosis and Hemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294553/ https://www.ncbi.nlm.nih.gov/pubmed/34280256 http://dx.doi.org/10.1182/blood.2021012938

Ejemplares similares

A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination
por: Handtke, Stefan, et al.
Publicado: (2021)

COVID-19 and VITT: same or different?
por: Arepally, Gowthami M.
Publicado: (2021)

Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022)

Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
por: Schönborn, Linda, et al.
Publicado: (2022)

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
por: Karnes, Jason H., et al.
Publicado: (2022)

Longitudinal Aspects of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

SARS-CoV-2 Infection in Patients with a History of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Greinacher, Andreas, et al.
Publicado: (2022)

The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies
por: Vayne, Caroline, et al.
Publicado: (2022)

Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources
por: Greinacher, Andreas, et al.
Publicado: (2022)

Vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Warkentin, Theodore E.
Publicado: (2022)

Impact of COVID-19 emergency on the psychological well-being of susceptible individuals
por: Stufano, Angela, et al.
Publicado: (2022)

Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate
por: Schöchl, Herbert, et al.
Publicado: (2017)

Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
por: Thomas, Kimberly A., et al.
Publicado: (2021)

Soluble protein C receptor: why?
por: Geiger, Margarethe
Publicado: (2008)

Screening platelet function in blood donors
por: Pedini, Pascal, et al.
Publicado: (2022)

Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trials
por: Khayat, Claudia Djambas, et al.
Publicado: (2022)

Decline in Pathogenic Antibodies over Time in VITT
por: Schönborn, Linda, et al.
Publicado: (2021)

Cytoskeleton Dependent Mobility Dynamics of FcγRIIA Facilitates Platelet Haptotaxis and Capture of Opsonized Bacteria
por: Palankar, Raghavendra, et al.
Publicado: (2022)

Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy
por: Greinacher, Andreas, et al.
Publicado: (2021)

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)

Divalent magnesium restores cytoskeletal storage lesions in cold-stored platelet concentrates
por: Aurich, Konstanze, et al.
Publicado: (2022)

An Epitope Platform for Safe and Effective HTLV-1-Immunization: Potential Applications for mRNA and Peptide-Based Vaccines
por: Lucchese, Guglielmo, et al.
Publicado: (2021)

Epidemiology of VITT
por: Pai, Menaka
Publicado: (2022)

Anti-neuronal antibodies against brainstem antigens are associated with COVID-19
por: Lucchese, Guglielmo, et al.
Publicado: (2022)

Author Correction: Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping
por: Sachs, Laura, et al.
Publicado: (2022)

Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping
por: Sachs, Laura, et al.
Publicado: (2022)

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)—Insights from Clinical Cases, In Vitro Studies and Murine Models
por: Dabbiru, Venkata A. S., et al.
Publicado: (2023)

The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies
por: Longstaff, Colin, et al.
Publicado: (2011)

Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain
por: Andersson, Helena M., et al.
Publicado: (2010)

Harmful or Physiologic: Diagnosing Fibrinolysis Shutdown in a Trauma Cohort With Rotational Thromboelastometry
por: Gomez-Builes, J. Carolina, et al.
Publicado: (2018)

Platelets inhibit apoptotic lung epithelial cell death and protect mice against infection-induced lung injury
por: Bain, William, et al.
Publicado: (2019)

Targeting complement activation in COVID-19
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2020)

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition
por: Yu, Jia, et al.
Publicado: (2020)

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

COVID-19 coagulopathy, thrombosis, and bleeding
por: Chan, Noel C., et al.
Publicado: (2020)

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
por: Hill, Jason B., et al.
Publicado: (2020)

A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies
por: Siegal, Deborah M., et al.
Publicado: (2020)

Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up
por: Salisbury, Richard, et al.
Publicado: (2020)

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
por: Giannis, Dimitrios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_689r5kn163g8p0gofkmnstc988